Optimal therapy for concomitant EGFR and TP53 mutated non-small cell lung cancer: a real-world study

Combination therapy had a higher efficacy than EGFR-TKI alone for patients with NSCLC having concomitant EGFR and TP53 mutations. Future prospective clinical trials are needed to determine the role of combination therapy for this patient population.